Company news
Medical Developments International Limited (ASX:MVP) news
Every Medical Developments International Limited press release and news update in one place — announcements, filings coverage, and company updates for invest...
View Medical Developments International Limited stock analysis →
Press releases & updates
MVP Announces FY26 Full Year Results
August 19, 2026
Appendix 4C and Quarterly Activity Report 30 June 2026
July 23, 2026
Appendix 4C and Quarterly Activity Report 31 March 2026
April 23, 2026
FY26 Half Year Presentation
February 18, 2026
FY26 Half Year Announcement
February 18, 2026
FY26 Half Year Report (including Appendix 4D)
February 18, 2026
Appendix 4C and Quarterly Activity Report 31 December 2025
January 29, 2026
Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO
January 7, 2026
Vaxxas Appoints Veteran Vaccine Leader to Board as Company Advances Needle-Free Vaccine Patch Towards Market
November 10, 2025
Appendix 4C and Quarterly Activity Report 30 September2025
October 9, 2025
FY25 Full Year Results
August 20, 2025
MVP Announces FY25 Full Year Results
August 20, 2025
FY25 Full Year Results Investor Presentation
August 20, 2025
Appendix 4C and Quarterly Activity Report - 30 June 2025
July 31, 2025
Appendix 4C and Quarterly Activity Report - 31 March 2025
April 28, 2025
FY25 Half Year Report (including Appendix 4D)
February 19, 2025
FY25 Half Year Presentation
February 19, 2025
FY25 Half Year Announcement
February 19, 2025
Appendix 4C and Quarterly Activity Report -31 December 2024
January 30, 2025
Appendix 4C & Quarterly Activity Report - 30 September 2024
October 22, 2024
FY24 Full Year Results Investor Presentation
August 25, 2024
FY24 Full Year Results
August 25, 2024
MVP Retail Entitlement Offer Booklet
August 1, 2024
Completion of Placement and Institutional Entitlement Offer
July 29, 2024
MVP Announces $10M Capital Raise
July 25, 2024
Investor Presentation - $10M Capital Raise
July 25, 2024
Appendix 4C & Quarterly Activity Report - 30 June 2024
July 25, 2024
Trading Halt
July 25, 2024
FY24 Asset Review and Non-cash Write-downs
July 11, 2024
Appendix 4C & Quarterly Activity Report - 31 March 2024
April 28, 2024
2024 Half Year Report (including Appendix 4D)
February 28, 2024
FY23 Full Year Results Investor Presentation
August 30, 2023
FY23 Full Year Accounts
August 30, 2023
MVP Announces FY23 Full Year Results
August 30, 2023
Response to ASX Price Query
July 25, 2023
US Penthrox Strategy
April 11, 2023
S&P DJI Announces March 2023 Quarterly Rebalance
March 3, 2023
2023 Half Year Presentation
February 23, 2023
2023 Half Year Report (including 4D)
February 23, 2023
2023 Half Year ASX Announcement
February 23, 2023
China Clinical Trials Discontinued
January 17, 2023
Chair and CEO Presentation to Shareholders
October 27, 2022
Security Class Reinstatement to Quotation MVPO
September 1, 2022
Completion of Retail Entitlement Offer
August 29, 2022
FY222 Full Year Results Investor Presentation
August 25, 2022
MVP Announces FY22 Full Year Results
August 25, 2022
FY22 Full Year Accounts
August 25, 2022
Security Class Suspension from Quotation MVPO
August 25, 2022
Prospectus - Entitlement Offer and Options
August 3, 2022
Investor Presentation - $30m Capital Raise and FY22 Guidance
August 3, 2022